Invitrogen Eyes Additional Instrument Offerings, Transplant Dx Market | GenomeWeb
NEW YORK (GenomeWeb News) - Less than two years after unveiling its initial offering of instruments, Invitrogen CEO Greg Lucier told investors during the firm’s first-quarter conference call last month that the development of small instrument systems would continue to be a focused part of Invitrogen’s growth strategy and that a transplant diagnostics system would soon hit the market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.